Stephens & Co. Reiterates Overweight on Codexis, Maintains $5 Price Target
Stephens & Co. analyst Steven Etoch reiterates Codexis (NASDAQ:CDXS) with a Overweight and maintains $5 price target.
Last updated: 2026-11-19 02:51:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Codexis, Inc. (CDXS) operates in the INDUSTRIAL ORGANIC CHEMICALS sector and is listed on NASDAQ. The stock is currently priced at $1.14, with a market capitalization of $116.17M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.90 to $2.98. This page covers its latest market performance, valuation, price trends and company information.
$116.17M | |
$1.07 | |
$1.18 | |
$1.02 | |
$1.07 | |
1.25M | |
902.96K | |
-- | |
$2.98 | |
$0.90 | |
-- | |
2026-09-30 |
Codexis, Inc. (CDXS) last closed at $1.14 as of 2026-11-19 00:44:00, up 6.07% ($0.06) from the previous close of $1.07.
During the latest regular trading session, CDXS traded between $1.02 and $1.18, with a volume of 1.25M shares. The closing price was near the upper end and near the lower end of its 52-week range.
Over the past seven days, Codexis, Inc. (CDXS) moved from $1.11 to $1.14, representing a gain of 2.43% ($0.03).
The stock traded between $0.90 and $1.20 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 1.26 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 11.4%
CDXS is currently trading at $1.14, placing it 11.4% of the way from its 52-week low of $0.90 to its 52-week high of $2.98. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.
| Industry | INDUSTRIAL ORGANIC CHEMICALS |
| Employees | 146 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to Codexis, Inc. and CDXS stock.
Stephens & Co. analyst Steven Etoch reiterates Codexis (NASDAQ:CDXS) with a Overweight and maintains $5 price target.
Gainers Cerenome (NASDAQ:CNSY) shares rose 39.5% to $1.07 during Friday's regular session. The market value of their outstanding shares is at $5.8 million. As per the press release, Q3 earnings came out today. SBC
Gainers SELLAS Life Sciences Gr (NASDAQ:SLS) stock rose 19.6% to $9.6 during Friday's pre-market session. The market value of their outstanding shares is at $1.6 billion. As per the news, the Q3 earnings report
Codexis (CDXS) reported a quarterly loss of $0.08 per share, beating consensus estimates of $0.09 loss, with revenues of $19.26 million exceeding expectations by 4.16%. Despite the earnings beat and consistent outperformance over four quarters, the stock has declined 40.1% year-to-date versus the S&P 500's 11.3% gain. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.
Codexis (NASDAQ:CDXS) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.10) by 20 percent. This is a 63.64 percent increase over losses of $(0.22) per share from the same
Eligible investors can buy real shares of Codexis, Inc. (CDXS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to CDXS, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between CDXS shares and USD.
CDXS Shares to USD
1.00 CDXS shares = 1.137 USD
Calculations are estimates based on the latest available price and are for reference only.